5th IBDH Annual Symposium
- Review the common extraintestinal manifestations in IBD apply practical approach to screen and intervene as needed
- Appraise the currently available evidence of the effect of Cannabis and supplements in IBD
- Discuss the newly approved and soon to be approved biologic and non-biologic therapies for IBD, including the risks, efficacy and special considerations when utilizing these therapies
- Describe and understand the comparative efficacy of the currently available therapies and the rationale for optimal positioning of these options in IBD today
- Incorporate the concept of treat to target in IBD clinical practice and evaluate effectively how to incorporate into IBD management and goals of care
- Examine the current management of fibrostenotic Crohn’s complications and apply best up-to-date medical and surgical treatment strategies
- Apply up-to-date practice in managing dysplasia in IBD from detection to endoscopic and surgical intervention
- Identify the most promising therapies including antibodies and small molecules in late-stage clinical development, with an emphasis on immunological targets and pharmacological properties
- Approach to Managing Common IBD Extraintestinal Manifestations
- Application of the Treat-To-Target Concept in Clinical Practice
- Comparative efficacy & positioning of IBD therapies today
- Managing Fibrostenotic Crohn's Disease Complications
- The Evolving World of non-biologic therapies
Speakers:Scott D. Lee
- Cannabis & Alternative Therapy in IBD: Good, Bad or Ugly
- Approach to managing Dysplasia in IBD
- Promising Pathways and Upcoming Agents in IBD
Board Certified in Internal medicine and Gastroenterology
Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation of America at Cedars-Sinai Medical Center in Los Angeles, California. She is board certified in Internal medicine and Gastroenterology. Dr. Abraham is a member of the American Gastroenterological Association, American College of Gastroenterology, Crohn’s and Colitis Foundation, American Society of Gastrointestinal Endoscopy, and chair of the South Texas Chapter of the Crohn’s and Colitis Foundation Medical Advisory Committee.
MD, MPH, Associate Professor of Clinical Medicine, Gastroenterologist
Dr. Anita Afzali is an Associate Professor of Clinical Medicine and a Gastroenterologist that specializes in Inflammatory Bowel Disease (IBD) at The Ohio State University Wexner Medical Center. She is the Director of Operations for the Division of Gastroenterology, Hepatology and Nutrition, as well as the Medical Director of the OSU Inflammatory Bowel Disease Center. She holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics. Her research interests include clinical outcomes and association of bowel and joint disease, influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials for investigational therapies. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Co-Chair of the Crohn’s & Colitis National Professional Education Committee and Member of the ACG Minority Affairs and Cultural Diversity committee.
MD, MSCE is an Associate Professor of Medicine
Mark Osterman, MD, MSCE is an Associate Professor of Medicine at the University of Pennsylvania Perelman School of Medicine where he serves as the Associate Director of IBD Research for the Penn Inflammatory Bowel Disease Center. He has been heavily involved in clinical research in inflammatory bowel disease for the last 10 years, with a focus on clinical trials of novel therapies, optimization and safety of medical therapies using observational studies, therapeutic drug monitoring of immunosuppressant medications, and mucosal healing. He has been lead PI or a steering committee member of a number of multi-center clinical trials. He is one of the nation’s pioneers of the study and use of proactive therapeutic drug monitoring for biologic therapy in IBD. His work has been funded by the AGA, NIH, CCFA, pharmaceutical industries, and private philanthropy. Dr. Osterman has recently served as Chair of the Chapter Medical Advisory Committee for the CCFA Philadelphia Chapter, for which he is also a board member.
Scott D. Lee
MD, Associate Professor of Medicine
Dr. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.
MD, Director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital
Ghassan Wahbeh, MD, is the director of the Inflammatory Bowel Disease Center at Seattle Children’s Hospital. He is professor of pediatrics and gastroenterology at the University of Washington School of Medicine. Dr. Wahbeh’s clinical focus is in advanced care for children adolescents and young adultswith Crohn’s Disease and Ulcerative Colitis, including advanced therapeutics and pre and post-surgery IBD management. Dr. Wahbeh’s research interests include advanced management of moderate and severe colitis in the outpatient and inpatient setting, managing complicated Crohn’s disease including fistulizing and stricturing phenotypes, mucosal healing in IBD, navigating surgical options in IBD and novel therapies. Dr. Wahbeh is actively involved as teaching faculty in medical student education, resident training and fellow physician specialty training. He is the honored recipient of the Outstanding Teaching Faculty Award, as well as the Family Choice Award, and the Northwest Crohns & Colitis Foundation service award. He continues to serve as a member of the National Professional Education Committee and the Northwest Medical Advisory Committee of the Crohns and Colitis Foundation of America.
Assistant Professor of Medicine
Dr. Barahimi is an assistant professor of medicine at the University of Washington with expertise in inflammatory bowel disease. She earned her bachelor’s degree and MD at the University of Washington. She went on to complete her residency in internal medicine and fellowship in gastroenterology at the University of Washington. In her clinical practice, she exclusively cares for patients with Crohn’s disease and ulcerative colitis. She is the principal investigator of IBD QORUS, a national quality improvement project that aims to improve the quality of care for patients with inflammatory bowel disease. She is also involved in clinical trials for new investigational therapies for inflammatory bowel disease. She is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology and American Society of Gastrointestinal Endoscopy.
Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC) and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials at the Robarts Research Institute, University of Western Ontario. His research efforts focus on the design and implementation of randomized controlled trials of therapy for inflammatory bowel disease. He has been the principal investigator on numerous large-scale randomized clinical trials.